Streetwise Reports' Article Archives — Current Month (16)
ProMIS Neurosciences discusses its four priority areas in 2021.
Shares of Avinger Inc. reached a new 52-week high after the company reported it initiated a full commercial launch of its Tigereye™ Image-Guided CTO Crossing Catheter system for diagnosing and treating peripheral artery disease.
Two year old DELIC Corp. has gotten in on the ground floor of the nascent psychedelic sector.
Shares of Inari Medical Inc. established a new 52-week high after the company reported that preliminary revenue in Q4/20 increased year-over-year by greater than 140%.
Shares of Mesoblast Ltd. traded 36% higher after the company reported positive results from its Phase 3 DREAM-HF study showing that a single dose of rexlemestrocel-L provided very significant decreases in heart attacks, strokes and cardiac death in patients diagnosed with chronic heart failure.
Private start-up RxMP's safe way to stop bleeding inexpensively is already the envy of bigger players, states Dr. KSS, MD, PhD, editor-in-chief of PubBio.co. Can it go the distance through proof of concept?
Algernon Pharmaceuticals provided an update detailing its plans for 2021 clinical trials.
Chimerix Inc. shares traded 65% higher after the company reported it entered into an agreement to acquire Oncoceutics Inc. in a combination stock and cash deal valued at $78 million plus milestone incentives totaling up to $360 million.
Small-Cap Tech Stock Sees Huge Rise; What's Next? (01/07/2021)
Technical analyst Clive Maund charts Leonovus and discusses what could lie ahead for the stock after it gained 150%.
The recently announced topline results from Axsome Therapeutics' MOVEMENT study are reviewed in a Ladenburg Thalmann report.
Independent financial analyst Matt Badiali profiles a small cap whose blood glucose monitoring system works with any smartphone.
Change Healthcare shares rose to a new 52-week high after the company reported it will be combining its operations with UnitedHealth's OptumInsight in an all cash purchase transaction for $25.75 per share.
Independent financial analyst Matt Badiali discusses how mCloud's technology is making it possible for office buildings to reopen during the pandemic.
Algernon Pharmaceuticals reports that it is aggressively advancing its repurposed drug, Ifenprodil.
Revive Therapeutics selects Dr. John Fahy, California-based pulmonary medicine expert and researcher, to join its team.
Pandion Therapeutics shares traded 35% higher after the company reported positive top-line data from its Phase 1a clinical study of PT101 for treating autoimmune diseases including ulcerative colitis and systemic lupus erythematosus.